Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development

Vaccine

Volumn 28, Issue 35, 2010, Pages 5676-5685

  Franco, David ^a   Li, Wenjing ^b   Qing, Fang ^a   Stoyanov, Cristina T ^a   Moran, Thomas ^b   Rice, Charles M ^a   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

17D; HIV 1; P24; Vaccine; Yellow fever virus

Indexed keywords

ANTIGEN P24; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NONSTRUCTURAL PROTEIN 1; UNCLASSIFIED DRUG; VIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIVE VACCINE; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; YELLOW FEVER FLAVIVIRUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; COMPARATIVE STUDY; DOSE RESPONSE; GENE VECTOR; GENETICS; HIV INFECTIONS; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; YELLOW FEVER VIRUS;

EID: 77955090269     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.052     Document Type: Article

References (48)

1. Cohen M.S., Hellmann N., Levy J.A., DeCock K., Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global epidemic. J Clin Invest 2008, 118(4):1244-1254.
2. McElrath M.J., De Rosa S.C., Moodel Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
3. Monath T.P. Yellow fever vaccine. Vaccines 2004, 1095-1176. Saunders, Philadelphia, WB. 4th ed. S. Ploktin, W. Orenstein (Eds.).
4. Co M.D., Terajima M., Cruz J., Ennis F.A., Rothman A. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 2002, 293:151-163.
5. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203(2):413-424.
6. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78(22):12497-12507.
7. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang M., et al. Replication of chimeric yellow fever virus-dengue serotypes 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005, 72:74-81.
8. Dean C.H., Alarcon J.B., Waterston A.M., Draper K., Early R., Guirakhoo F., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates. Hum Vaccine 2005, 1(3):106-111.
9. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccine 2006, 2(2):60-67.
10. Lai C.J., Monath T.P. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 2003, 61:469-509.
11. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006, 103(17):6694-6699.
12. Pugachev K.V., Guirakhoo F., Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005, 18:387-394.
13. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345(2):299-304.
14. + T cell responses in rhesus macaques. J Virol 2010, 84(7):3699-3706.
15. Rice C.M., Grakoui A., Galler R., Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1989, 1:285-296.
16. Agapov E.V., Murray C.L., Frolov I., Qu L., Myers T.M., Rice C.M. Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus. J Virol 2004, 78(5):2414-2425.
17. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 2006, 80:1734-1741.
18. Amberg S.M., Rice C.M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J Virol 1999, 73:8083-8094.
19. Maciel M., Kellathur S.N., Chikhlikar P., Dhalia R., Sidney J., Sette A., et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 2008, 378(1):105-117.
20. Niedrig M., Kürsteiner O., Herzog C., Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 2008, 15(2):177-181.
21. Ronaldo M.C., Mello S.M., Trindade G.F., Rangel A.A., Duarte A.S., Oliveira P.J., et al. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J 2007, 30(4):115.
22. Corver J., Lenches E., Smith K., Robison R.A., Sando T., Strauss E.G., et al. Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization. J Virol 2003, 77(3):2265-2270.
23. Hahn C.S., Hahn Y.S., Rice C.M., Lee E., Dalgarno L., Strauss E.G., et al. Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol 1987, 198:33-41.
24. Khromykh A.A., Meka H., Guyatt K.J., Westaway E.G. Essential role of cyclization sequences in flavivirus RNA replication. J Virol 2001, 75:6719-6728.
25. Daniel M.D., Kirchhoff F., Csajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(5090):1938-1941.
26. Marchevsky R.S., Freire M.S., Coutinho E.S., Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 2003, 316:55-63.
27. + T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(5):710-722.
28. Bonaldo M.C., Garratt R.C., Caufour P.S., Freire M.S., Rodrigues M.M., Nussenzweig R.S., et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol 2002, 315:873-885.
29. Tao D., Barba-Spaeth G., Rai U., Nussenzweig V., Rice C.M., Nussenzweig R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 2005, 201(2):201-209.
30. Barba-Spaeth G., Longman R.S., Albert M.L., Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005, 202(9):1179-1184.
31. McAllister A., Arbetman A.E., Mandl S., Pena-Rossi C., Andino R. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 2000, 74(19):9197-9205.
32. Lefeuvre A., Marianneau P., Deubel V. Current assessment of yellow fever and yellow fever vaccine. Curr Infect Dis Rep 2004, 6:96-104.
33. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205(13):3119-3131.
34. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(1):116-125.
35. Minton K. HIV: bigger T-cell response not necessarily better. Nat Rev Immunol 2001, 7:88-89.
36. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
37. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris P.J., Johnston M.N., et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 2004, 78:4463-4477.
38. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
39. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001, 75:11983-11991.
40. + T cells: correlation with viral load. J Virol 2004, 78:3233-3243.
41. Rolland M., Heckerman D., Deng W., Rousseau C.M., Coovadia H., Bishop K., et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008, 3(1):e1424.
42. + T cells in primary HIV-1 infection. J Virol 2003, 77:6867-6878.
43. Apostolopoulos V., Weiner D.B. Development of more efficient and effective DNA vaccines. Expert Rev Vaccines 2009, 8(9):1133-1134.
44. Ramanathan M.P., Kutzler M.A., Kuo Y.C., Yan J., Liu H., Shah V., et al. Co-immunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 2009, 27(32):4370-4380.
45. Yin J., Dai A., Laddy D.J., Yan J., Arango T., Khan A.S., et al. High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model. Virology 2009, 393(1):49-55.
46. + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006, 203:607-617.
47. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(4):247-258.
48. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(7):843-850.